Alteration of HLA-F and HLA i antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 82-89

  Zhang, X ^a   Lin, A ^a   Zhang, J G ^a   Bao, W G ^a   Xu, D P ^a   Ruan, Y Y ^a   Yan, W H ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

esophageal squamous cell carcinoma; HLA; prognosis

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; HLA F ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TISSUE SECTION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; UP-REGULATION;

EID: 84868206707     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27621     Document Type: Article

References (28)

1. Stahl M,. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer? Ann Oncol 2010; 21: vii283-5.
2. Garrido F, Algarra I, García-Lora AM,. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother 2010; 59: 1601-6.
3. Mizukami Y, Kono K, Maruyama T, et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008; 99: 1462-7.
4. Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001; 22: 1615-23.
5. Liu Q, Hao C, Su P, et al. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol 2009; 44: 960-9.
6. Ayshamgul H, Ma H, Ilyar S, et al. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl) 2011; 124: 341-6.
7. Chang CC, Campoli M, Ferrone S,. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 2004; 16: 644-50.
8. Campoli M, Ferrone S,. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 2011; 33: 321-34.
9. Hayakawa S,. No cancer in cancers: evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. Med Hypotheses 2006; 66: 888-97.
10. Wischhusen J, Waschbisch A, Wiendl H,. Immune-refractory cancers and their little helpersa-an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Biol 2007; 17: 459-68.
11. Lo Monaco E, Tremante E, Cerboni C, et al. Human leukocyte antigen e contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 2011; 13: 822-30.
12. Lepin EJ, Bastin JM, Allan DS, et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30: 3552-61.
13. Yan WH,. Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett 2011; 311: 123-30.
14. Yan WH,. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets 2011; 11: 76-89.
15. de Kruijf EM, Sajet A, van Nes JG, et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010; 185: 7452-9.
16. Lin A, Zhang X, Ruan YY, et al. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer 2011; 74: 504-9.
17. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 6th edn. New York, NY: Wiley-Liss, 2002. 81-3.
18. Gomes AQ, Correia DV, Silva-Santos B,. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep 2007; 8: 1024-30.
19. Hunt JS,. Stranger in a strange land. Immunol Rev 2006; 213: 36-47.
20. Geraghty DE, Wei XH, Orr HT, et al. Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J Exp Med 1990; 171: 1-18.
21. Lury D, Epstein H, Holmes N,. The human class I MHC gene HLA-F is expressed in lymphocytes. Int Immunol 1990; 2: 531-7.
22. Wainwright SD, Biro PA, Holmes CH,. HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol 2000; 164: 319-28.
23. Lee N, Geraghty DE,. HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003; 171: 5264-71.
24. Lee N, Ishitani A, Geraghty DE,. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010; 40: 2308-18.
25. Clements CS, Kjer-Nielsen L, McCluskey J, et al. Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol 2007; 68: 220-6.
26. Tanaka K, Tsuchikawa T, Miyamoto M, et al. Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol 2012; 40: 965-74.
27. Hosch SB, Izbicki JR, Pichlmeier U, et al. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 1997; 74: 582-7.
28. Rockett JC, Darnton SJ, Crocker J, et al. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J Clin Pathol 1995; 48: 539-44.